Cilostazol Verse Asprin for Vascular Dementia in Poststroke Patients With White Matter Lesions "CAVAD"

Completed

Phase 4 Results N/A

Trial Description

The purpose of this study is to evaluate the efficacy of PDE-3 inhibitor, cilostazol, in prevention and treatment of vascular dementia, in those with brain white matter lesions and vascular risk factors.

Conditions

Interventions

  • Cilostazol (PletalĀ®)Drug
    Other Names: Claudiasil
    Intervention Desc: Cilostazol 100 mg bid for 12 months
    ARM 1: Kind: Experimental
    Label: 1
    Description: Cilostazol
  • Aspirin Drug
    Other Names: Aspirin at bedtime
    Intervention Desc: Aspirin 100 mg qd for 12 months
    ARM 1: Kind: Experimental
    Label: 2
    Description: Asprin

Trial Design

  • Allocation: Randomized
  • Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
  • Purpose: Treatment
  • Endpoint: Safety Study
  • Intervention: Parallel Assignment

Outcomes

Type Measure Time Frame Safety Issue
Primary changes of the scores of MMSE, MOCA,CDR,and Blessed-Roth one year No
Secondary stroke recurrence, other vascular ischemic events, bleeding events one year Yes

Sponsors